Hangzhou Innogate Pharma Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Apr 2036
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 23, 2027The maintenance fee for Heterocycles useful as IDO and TDO inhibitors (US 10,358,451) comes due Jan 23, 2027. Unpaid by Jul 23, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,358,451 | Heterocycles useful as IDO and TDO inhibitors In force · USPTO record | In force | USPTO record | |
| US 10,730,887 | Compound containing tricyclic heteroaryl group In force · USPTO record | In force | USPTO record | |
| US 10,968,234 | Compound containing tricyclic heteroaryl group In force · USPTO record | In force | USPTO record | |
| US 11,142,535 | Heterocyclic compound as Syk inhibitor and/or Syk-HDAC dual inhibitor In force · USPTO record | In force | USPTO record | |
| US 11,352,353 | Heterocyclic compound serving as FGFR4 inhibitor In force · USPTO record | In force | USPTO record | |
| US 11,266,640 | Polycyclic compound acting as IDO inhibitor and/or IDO-HDAC dual inhibitor In force · USPTO record | In force | USPTO record | |
| US 12,358,911 | Heterocyclic comipound as CDK-HDAC dual pathway inhibitor In force · USPTO record | In force | USPTO record | |
| US 12,415,797 | Heterocyclic compound as CDK-HDAC double-channel inhibitor In force · USPTO record | In force | USPTO record | |
| US 12,589,092 | Polycyclic Compound Acting as Kinase Inhibitor In force · High confidence | In force | High confidence |
Also on record, not counted in the 9: 2 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 3 no status recorded